Evaxion A (EVAX) Interest & Investment Income (2020 - 2026)
Evaxion A's (EVAX) quarterly Interest & Investment Income came in at $305000.0 in Q1 2026, down 87.77% YoY from $2.5 million in Q1 2025, and down 51.28% on a QoQ basis from $626000.0 in Q4 2025.
Evaxion A (EVAX) Interest & Investment Income (2020 - 2026) Analysis & Trends
Evaxion A (EVAX) has 7 years of Interest & Investment Income data on file, last reported at $305000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 87.77% year-over-year to $305000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (up 61.24% YoY) and the FY2025 annual result came in at $6.4 million, down 2.23% from the prior year.
- Interest & Investment Income eased to $305000.0 in Q1 2026, from $626000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $5.6 million in Q1 2024 to a low of $47000.0 in Q2 2023.
- A 5-year average of $1.1 million and a median of $559000.0 in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2023 — Interest & Investment Income sank 96.95% — and 2025, when it surged 3102.38%.
- Tracing EVAX's Interest & Investment Income over 5 years: stood at $70000.0 in 2022, then soared by 698.57% to $559000.0 in 2023, then increased by 3.4% to $578000.0 in 2024, then gained by 8.3% to $626000.0 in 2025, then tumbled by 51.28% to $305000.0 in 2026.
- The last three Interest & Investment Income figures came in at $305000.0 (Q1 2026), $626000.0 (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Evaxion A | 27.61 Mn | 27.61 Mn | - | 305,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 305,000.00 |
| Dec 31, 2025 | 626,000.00 |
| Sep 30, 2025 | 2.69 Mn |
| Jun 30, 2025 | 1.82 Mn |
| Mar 31, 2025 | 2.49 Mn |
| Dec 31, 2024 | 578,000.00 |
| Sep 30, 2024 | 84,000.00 |
| Jun 30, 2024 | 220,000.00 |
| Mar 31, 2024 | 5.62 Mn |
| Dec 31, 2023 | 559,000.00 |
| Sep 30, 2023 | 72,000.00 |
| Jun 30, 2023 | 47,000.00 |
| Mar 31, 2023 | 285,000.00 |
| Dec 31, 2022 | 70,000.00 |
| Sep 30, 2022 | 703,000.00 |
| Jun 30, 2022 | 1.54 Mn |
| Mar 31, 2022 | 519,000.00 |
| Dec 31, 2021 | 746,000.00 |
| Sep 30, 2021 | 1.29 Mn |
| Jun 30, 2021 | 1.01 Mn |